Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Partner Vanda Pharmaceuticals published the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence. The findings from this pivotal Phase 3 study are included in the Biologics License Application submitted to the FDA, which has a target action date of December 12, 2026.
Key figures
- Drug Name
- Imsidolimab
- Phase Of Trial
- Phase III
- Journal
- NEJM Evidence
- Indication
- Generalized Pustular Psoriasis (GPP)
- Pdufa date
- December 12, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.